Pharmacyclics (PCYC) Q4 2012 Earnings Call September 06, 2012 4:30 pm ET Executives Rainer M. Erdtmann - Principal Accounting Officer, Vice President of Finance & Administration and Secretary Robert W. Duggan - Chairman and Chief Executive Officer Mahkam Zanganeh - Chief Operating Officer Jesse Seton McGreivy - Vice President of Clinical Science Joseph J. Buggy - Vice President of Research Analysts Michael J. Yee - RBC Capital Markets, LLC, Research Division Brian Skorney - Brean Murray, Carret & Co., LLC, Research Division Alan Carr - Needham & Company, LLC, Research Division Michael G. King - Rodman & Renshaw, LLC, Research Division Howard Liang - Leerink Swann LLC, Research Division Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division Joshua Schimmer - Lazard Capital Markets LLC, Research Division Brian Lian - SunTrust Robinson Humphrey, Inc., Research Division PresentationOperator
Greetings, and welcome to the Pharmacyclics Fourth Quarter and Fiscal Year End 2012 Conference Call. [Operator Instructions] A brief question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ramses Erdtmann, Vice President, Finance for Pharmacyclics. Thank you. Mr. Erdmann, you may begin. Rainer M. Erdtmann Yes. Thank you, Robin. Good afternoon, and thank you for joining us for our conference call today. With me on the call today and available to answer questions are our CEO and Chairman of the Board, Bob Duggan; our Chief Operating Officer, Dr. Maky Zanganeh; our Executive Vice President, Paula Boultbee; our Executive Vice President of Finance, Josh Brumm; Dr. Jesse McGreivy, our Vice President of Clinical Science; Dr. Maria Fardis, our Vice President of Alliance and Global Project Management; and our Vice President of Research, Dr. Joe Buggy.